CSF2 and neuroblastoma: Preliminary efficacy results of naxitamab+GM-CSF from two independently conducted phase 2 clinical trials (Trial 12-230 [NCT01757626] and Trial 201 [NCT03363373]) in patients with R/R HR neuroblastoma and residual disease in bone/BM supported the accelerated US Food and Drug Administration approval for this vulnerable population35.